Key Highlights

  • Shares are trading down 26.52% at $14.51 versus a prior close of $19.74.
  • Management expects 2027 growth to be temporarily held to low single digits.
  • Fiscal 2026 guidance was reiterated, with Revenue of $1.26 billion to $1.28 billion.

Stevanato Group (NYSE:STVN) shares are trading down 26.52% at $14.51 today after a third-quarter report that came with a warning on 2027. The stock sits near the bottom of its 52-week range of $12.89 to $27.00 on Volume roughly 10 times average, and the drop looks company-specific, since the broader market was higher.

Stevanato Group is an Italian provider of integrated drug containment, drug delivery and diagnostic solutions for the pharmaceutical, biotechnology and life sciences industries, founded in 1949 and headquartered in Piombino Dese, Italy. It has about 6,010 employees and operates two segments, Biopharmaceutical and Diagnostic Solutions covering vials, cartridges, syringes and auto-injectors, and Engineering covering inspection, assembly and packaging machinery.

Lower GLP-1 Volumes From One Customer Cap 2027 Growth

Management said lower GLP-1 syringe volumes from one large customer will temporarily moderate 2027 growth to low single digits, versus a long-range plan of high single to low double digits. GLP-1 products were about 17% to 18% of third-quarter revenue, and most of the shortfall is expected to be backfilled, with growth normalizing in 2028.

Offsetting that, non-GLP-1 Biologics grew more than 30% in the third quarter and about 13% year to date. Variable compensation tied to lower GLP-1 volumes was recorded in the second and third quarters. Full 2027 guidance will come in early March.

Third-Quarter Results and Reiterated Full-Year Guidance

Third-quarter revenue rose 8% to $326.1 million, both reported and organic. The Biopharmaceutical and Diagnostic Solutions segment grew 11% organically, while Engineering fell 12% to $32 million. High-value solutions were 46% of revenue at $149.4 million, adjusted EBITDA rose 14% to $88.8 million at a 27.2% margin, up 150 basis points, and adjusted diluted EPS was $0.16. Free Cash Flow was $21.7 million.

Fiscal 2026 guidance was reiterated, with revenue of $1.26 billion to $1.28 billion, adjusted EBITDA of $335 million to $345.2 million and adjusted diluted EPS of $0.60 to $0.62. The Biopharmaceutical and Diagnostic Solutions segment is now expected to grow organically in double digits at the midpoint, while Engineering revenue guidance was cut to $124 million to $134 million on delayed orders from the same large GLP-1 customer.

Engineering Order Delays Weigh on 2026 and 2027

Engineering order conversion is weak, with delays from a key customer pressuring 2026 and 2027, and management is still assessing strategic Options for the segment. Fishers reached Gross Profit breakeven in the third quarter and is expected to be fully ramped by the end of 2028. Before the report, analysts had been mostly bullish, with a mean target near $24.84.

March Guidance Will Test the Backfill Argument

Investors will look to the early-March 2027 guidance for evidence that the GLP-1 shortfall is being backfilled and that margins can keep expanding. For now, the sell-off leaves the shares near the bottom of their 52-week range.